ASA! oh FLIP FLOP ASA! What are you up to????

ASA! we are going to do as the pic says and put you in the spotlight and ask about the following press release :

1.) What sort of financial connection is between you before, now, or to come in the future with this company and/or it's parent company?

2.) Your duties as entailed are : "Mr. Hutchinson will be charged, along with his fellow board members, withassisting in the development of a plan to disseminate the proprietary andpotentially life-saving Radilex(TM)/Viprovex(TM) in the event of a biologicalor nuclear disaster."

Since you are seeking to be Arkansas Governor, does that not conflict with your duties now?

3.) If theres nothing unbecoming, why is there NO mention of your Gubernatorial candidacy, although your Congressional, Cabinet tenures, and other professional offices held ARE mentioned?

Also, since technology has a way of disappearing, we are printing the entire press release for the press, visitors, and voters to see :

Former Congressman, Under Secretary of the Dept. of Homeland Security Joins Board as Advisor SCOTTSDALE, Ariz., Jan. 5 /PRNewswire/ -- Research and developmentbiotechnology company ImmuneRegen BioSciences, a wholly owned subsidiary of IRBioSciences Holdings, Inc. (IRBO), has named Asa Hutchinson, a formercongressman of Arkansas and former Under Secretary of the Department of Homeland Security, as a senior advisor to its Bioterrorism PreparednessAdvisory Board. Mr. Hutchinson will be charged, along with his fellow board members, withassisting in the development of a plan to disseminate the proprietary andpotentially life-saving Radilex(TM)/Viprovex(TM) in the event of a biologicalor nuclear disaster. The ImmuneRegen Bioterrorism Preparedness Advisory Boardwill serve as a resource to the leadership of IR as it works to developbiological countermeasures in the current threat environment. "Mr. Hutchinson's in-depth background in Homeland Security are ofincalculable importance to our Advisory Board," said Michael K. Wilhelm,ImmuneRegen's CEO. "His knowledge and experience will benefit us greatly,especially in helping to guide our strategic plan related to Bioshield IIlegislation and in our pursuit to make Radilex a staple in all nationalemergency preparedness stockpiles." Radilex is a treatment currently in development to counteract the effectsof lethal radiation dosages. Having undergone its seventh stage of testing,Radilex is heading into its final phase of rodent studies with Oak RidgeNational Laboratories. "The U.S. can and should do more to aid the development and procurement ofeffective countermeasures for multiple homeland security threats. Thesethreats include chemical agents, Acute Radiation Sickness (ARS) from a dirtybomb or nuclear disaster, and infectious disease/biological warfarescenarios," said Hutchinson. "If the country were under a biological,chemical or radiological attack today, I fear we would not have sufficientstockpiles of medicine to meet the needs of the nation. This is why Iaccepted ImmueRegen's invitation to help develop public-private partnershipsthat will better protect the country from terrorist attack." The U.S. Senate confirmed Mr. Hutchinson as Under Secretary of HomelandSecurity in January 2003, shortly after the department was created. As one ofthe nation's top-ranking homeland security officials after Secretary TomRidge, he was responsible for more than 110,000 federal employees housed insuch agencies as the Transportation Security Administration, Customs andBorder Protection, Immigration and Customs Enforcement, and the Federal LawEnforcement Training Center. He was responsible for managing and coordinatingthe overall security of U.S. borders and transportation systems, settingimmigration enforcement policies and priorities, and developing andimplementing visa security programs. During his tenure as Under Secretary, Mr. Hutchinson modernized borderinspections through the successful reorganization of formerly fragmentedborder agencies into one unified inspection force under Customs and BorderProtection. He also advanced the use of new border technology, includingdevelopment of the US-VISIT program -- a historic biometric entry-exit systemfor foreign visitors to the United States. About ImmuneRegen BioSciences, Inc. IR BioSciences Holdings Inc., through its wholly owned subsidiaryImmuneRegen BioSciences, Inc., is developing Homspera(TM) and its derivativesRadilex(TM) and Viprovex(TM) as a family of countermeasures for multiplehomeland security threats, including chemical agents, Acute Radiation Sickness(ARS) from a dirty bomb or nuclear disaster, and infectious disease/biologicalwarfare scenarios. This positions the base compound Homspera as a potentialUniversal Protectant. Homspera is derived from modified homeostatic SubstanceP, a naturally occurring peptide immunomodulator and homeostatic compound withthe dual effect of improving pulmonary function and the stimulation of thehuman immune system. Further advances with the Office of Naval Research (ONR)and the U.S. Air Force are currently being pursued. The development ofHomspera and its derivatives is pursuant to the U.S. Food and DrugAdministration's "animal efficacy" rule, which allows an expedited developmentand approval process. In addition, these compounds are candidates for theStrategic National Stockpile under current BioShield law. For moreinformation, please visit the company's website at http://www.immuneregen.com. Statements about the Company's future expectations, including futurerevenues and earnings, and all other statements in this press release otherthan historical facts, are "forward-looking statements" within the meaning ofSection 27A of the Securities Act of 1933, Section 21E of the SecuritiesExchange Act of 1934, and as that term is defined in the Private SecuritiesLitigation Reform Act of 1995. The Company intends that such forward-lookingstatements be subject to the safe harbors created thereby. The Company'sactual results could differ materially from expected results as a result of anumber of factors, including the uncertainties inherent in researchcollaborations, clinical trials and product development programs, theevaluation of potential opportunities, the level of corporate expenditures,capital market conditions, and others set forth in the Company's periodicreport on Form 10-Q for the three months ended June 30, 2005 as filed with theSecurities and Exchange Commission. Contact: W. Jason Grimley Spelling Communications 310-477-9500 jgrimley@spellcom.com